

IN THE CLAIMS:

Please add the following new claims:

41. (New) The conjugate of claim 1, with the proviso that the tissue is not plasma.
42. (New) The conjugate of claim 1, wherein the conjugate includes 1α -(OH)-24-aminoalkyl-1,1-bisphosphonate- D_2 , 1-aminoalkyl-1,1-bisphosphonate-24-(OH)- D_2 , 1α ,24-(OH) $_2$ -3-aminoalkyl-1,1-bisphosphonate- D_2 , 1α -aminoalkyl-1,1-bisphosphonate-25-(OH)- D_3 , 1α ,25-(OH) $_2$ -3-aminoalkyl-1,1-bisphosphonate- D_3 , 1α -(OH)-25-aminoalkyl-1,1-bisphosphonate- D_3 , and combinations thereof.
43. (New) The conjugate of claim 20, with the proviso that the tissue is not plasma.
44. (New) A conjugate comprising at least one vitamin D moiety associated with a target molecule moiety having an affinity for a tissue of interest, the target molecule moiety including at least one of tetracycline, calcitonin, a bisphosphonate, a phosphate, polyaspartic acid, polyglutamic acid, an aminophosphosugar, osteonectin, bone sialoprotein, osteopontin, protein with bone mineral binding domains, estrogen, a steroid, dehydroepiandrosterone (DHEA), a metal ion-amino acid chelate, an antibody and combinations thereof.
45. (New) The conjugate of claim 44, wherein the conjugate includes 1α -(OH)-24-aminoalkyl-1,1-bisphosphonate- D_2 , 1-aminoalkyl-1,1-bisphosphonate-24-(OH)- D_2 , 1α ,24-(OH) $_2$ -3-aminoalkyl-1,1-bisphosphonate- D_2 , 1α -aminoalkyl-1,1-bisphosphonate-25-(OH)- D_3 , 1α ,25-(OH) $_2$ -3-aminoalkyl-1,1-bisphosphonate- D_3 , 1α -(OH)-25-aminoalkyl-1,1-bisphosphonate- D_3 , and combinations thereof.
46. (New) The conjugate of claim 44, wherein the target molecule moiety is a bisphosphonate moiety.
47. (New) The conjugate of claim 46, wherein said bisphosphonate is linked to said vitamin D moiety at a position on the vitamin D moiety which is C-1, C-3, C-24 or C-25.